menu
    • menu
    [{"orgOrder":0,"company":"Estrella Biopharma","sponsor":"Eureka Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"EB103","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Estrella Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Estrella Biopharma \/ Eureka Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Estrella Biopharma \/ Eureka Therapeutics"},{"orgOrder":0,"company":"Estrella Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Private Placement","leadProduct":"EB103","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Estrella Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Estrella Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Estrella Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Estrella Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"EB103","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Estrella Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Estrella Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Estrella Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Estrella Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"EB103","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Estrella Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Estrella Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Estrella Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Estrella Biopharma","sponsor":"TradeUP Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Merger","leadProduct":"EB103","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Estrella Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Estrella Biopharma \/ TradeUP Acquisition Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Estrella Biopharma \/ TradeUP Acquisition Corp."},{"orgOrder":0,"company":"Estrella Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"EB103","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Estrella Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Estrella Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Estrella Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Estrella Biopharma","sponsor":"TradeUP Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Merger","leadProduct":"EB103","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Estrella Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Estrella Biopharma \/ TradeUP Acquisition Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Estrella Biopharma \/ TradeUP Acquisition Corp."}]

    Find Clinical Drug Pipeline Developments & Deals by Estrella Biopharma

    Menu

    Estrella Biopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Estrella Biopharma

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Estrella Biopharma

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EB103

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : $3.3 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Estrella Announces Approximately $3.35 Million Private Placement

                            Details : Estrella intends to use the net proceeds to support the completion of Phase I evaluating EB103, a CD19-Redirected ARTEMIS T-cell therapy, in adult patients with B-cell non-Hodgkin’s lymphoma.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            June 03, 2025

                            Lead Product(s) : EB103

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : $3.3 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Estrella Biopharma

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Estrella Biopharma

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EB103

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Estrella Completes STARLIGHT-1 First Dose, Gains Nod for Higher Dose Cohort

                            Details : EB103 is a T-cell therapy, once infused, it seeks out CD19-positive cancer cells, bind to these cells, and destroy them. It is being investigated for B-Cell non-hodgkin's lymphoma.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            February 21, 2025

                            Lead Product(s) : EB103

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Estrella Biopharma

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Estrella Biopharma

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EB103

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Estrella Immunopharma Reports Complete Response in ARTEMIS® T-Cell Trial

                            Details : EB103 is a T-cell therapy, also referred to as Estrella’s CD19-Redirected ARTEMIS T-cell therapy. It is evaluated for the treatment of r/r B-Cell Non-Hodgkin's Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 27, 2024

                            Lead Product(s) : EB103

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Estrella Biopharma

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Estrella Biopharma

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EB103

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Eureka Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

                            Details : EB103 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lymphoma, B-Cell.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 02, 2024

                            Lead Product(s) : EB103

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Eureka Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Estrella Biopharma

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Estrella Biopharma

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EB103

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : TradeUP Acquisition Corp.

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination

                            Details : Estrella is developing CD19-targeted ARTEMIS T-cell therapies under certain license agreements with the capacity to address treatment challenges for patients with blood cancers and solid tumors with its lead asset EB103 and EB104.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            September 29, 2023

                            Lead Product(s) : EB103

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : TradeUP Acquisition Corp.

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Estrella Biopharma

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Estrella Biopharma

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EB103

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Estrella Biopharma Announces FDA Clearance of IND Application for Phase I/II Clinical Trial (Starlight-1) of E...

                            Details : EB103, a T-cell therapy which activates and regulates upon engagement with cancer targets that use a cellular mechanism more closely resembling the one from an endogenous T-cell receptor. It seek out CD19-positive cancer cells, bind to these cells, and d...

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            March 08, 2023

                            Lead Product(s) : EB103

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Estrella Biopharma

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Estrella Biopharma

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EB103

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : TradeUP Acquisition Corp.

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Estrella Biopharma, Inc., a Biopharmaceutical Company to Become a Publicly Traded Company Via Merger with Trad...

                            Details : Estrella is developing CD19-targeted ARTEMIS T-cell therapies under certain license agreements with the capacity to address treatment challenges for patients with blood cancers and solid tumors with its lead asset EB103 and EB104.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            October 03, 2022

                            Lead Product(s) : EB103

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : TradeUP Acquisition Corp.

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth